HC Wainwright Weighs in on Keros Therapeutics, Inc.’s Q2 2023 Earnings (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) – Investment analysts at HC Wainwright dropped their Q2 2023 earnings estimates for shares of Keros Therapeutics in a report released on Monday, May 8th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.43) per share for the quarter, down from their prior forecast of ($1.28). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.72) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q3 2023 earnings at ($1.50) EPS, Q4 2023 earnings at ($1.31) EPS, FY2023 earnings at ($5.60) EPS, FY2024 earnings at ($5.45) EPS, FY2025 earnings at ($5.30) EPS, FY2026 earnings at ($4.22) EPS and FY2027 earnings at ($0.73) EPS.

Several other research analysts have also commented on KROS. Piper Sandler dropped their price target on shares of Keros Therapeutics from $120.00 to $110.00 in a research note on Friday, May 5th. Cowen initiated coverage on shares of Keros Therapeutics in a research note on Tuesday, February 14th. They set an “outperform” rating on the stock. Finally, Cowen began coverage on shares of Keros Therapeutics in a research note on Tuesday, February 14th. They set an “outperform” rating on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Buy” and an average target price of $103.75.

Keros Therapeutics Stock Up 1.7 %

Shares of KROS opened at $45.02 on Wednesday. The company’s fifty day moving average is $44.00 and its 200-day moving average is $48.03. Keros Therapeutics has a 12 month low of $24.38 and a 12 month high of $59.96. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -10.23 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS – Get Rating) last released its earnings results on Thursday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.12). During the same period in the prior year, the firm posted ($1.01) EPS.

Institutional Trading of Keros Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KROS. Point72 Hong Kong Ltd bought a new position in shares of Keros Therapeutics during the 2nd quarter worth about $28,000. Almanack Investment Partners LLC. bought a new position in shares of Keros Therapeutics during the 3rd quarter worth about $32,000. Tower Research Capital LLC TRC lifted its holdings in shares of Keros Therapeutics by 134.6% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,140 shares of the company’s stock worth $48,000 after acquiring an additional 654 shares during the period. Lazard Asset Management LLC bought a new position in shares of Keros Therapeutics during the 1st quarter worth about $67,000. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Keros Therapeutics during the 3rd quarter worth about $80,000. 64.14% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

(Get Rating)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis.